TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?

被引：41

作者：

Gram, Dorte X. ^{[1
]}

Holst, Jens J. ^{[2
]}

Szallasi, Arpad ^{[3
]}

机构：

[1] Pila Pharma, Malmo, Sweden

[2] Univ Copenhagen, Panum Inst, Copenhagen, Denmark

[3] Baptist Med Ctr, Jacksonville, FL USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2017年 / 23卷 / 11期

关键词：

GENE-RELATED PEPTIDE; SENSORY NERVE DESENSITIZATION; SUBSTANCE-P; INSULIN-SECRETION; GLUCOSE-TOLERANCE; PERIPHERAL NEUROPATHY; INFLAMMATORY MARKERS; VANILLOID RECEPTOR-1; CAPSAICIN RECEPTORS; ISLET INFLAMMATION;

D O I：

10.1016/j.molmed.2017.09.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is a polygenic disease with a chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents with proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt disease progression and improve glucose metabolism. Thus, we propose that TRPV1 antagonists merit further study as novel therapeutic approaches to potentially treat T2D and its comorbidities.

引用

页码：1002 / 1013

页数：12

共 50 条

[31] GDF15: a potential therapeutic target for type 1 diabetes
Sarkar, Soumyadeep
Melchior, John T.
Henry, Hayden R.
Syed, Farooq
Mirmira, Raghavendra G.
Nakayasu, Ernesto S.
Metz, Thomas O.
EXPERT OPINION ON THERAPEUTIC TARGETS, 2022, 26 (01) : 57 - 67
[32] Remote activation of TRPV1 for therapeutic effect
Sauer, Jeremy
Stanley, Sarah A.
Kane, Ravindra
Friedman, Jeffrey M.
Dordick, Jonathan
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
[33] TRPV1 Receptors as Therapeutic Targets in Pruritus
Staender, S.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 62 - 62
[34] TRPV1 Ion Channel: Structural Features, Activity Modulators, and Therapeutic Potential
Irina N. Gladkikh
Oksana V. Sintsova
Elena V. Leychenko
Sergey A. Kozlov
Biochemistry (Moscow), 2021, 86 : S50 - S70
[35] TRPV1 Ion Channel: Structural Features, Activity Modulators, and Therapeutic Potential
Gladkikh, Irina N.
Sintsova, Oksana, V
Leychenko, Elena, V
Kozlov, Sergey A.
BIOCHEMISTRY-MOSCOW, 2021, 86 (SUPPL 1) : S50 - S70
[36] TRPV1 antagonists: the challenges for therapeutic targeting
Khairatkar-Joshi, Neelima
Szallasi, Arpad
TRENDS IN MOLECULAR MEDICINE, 2009, 15 (01) : 14 - 22
[37] TRPV2: A Cancer Biomarker and Potential Therapeutic Target
Siveen, Kodappully S.
Nizamuddin, Parveen B.
Uddin, Shahab
Al-Thani, Mohamed
Frenneaux, Michael Paul
Janahi, Ibrahim A.
Steinhoff, Martin
Azizi, Fouad
DISEASE MARKERS, 2020, 2020
[38] NLRP3, a Potential Therapeutic Target for Type 2 Diabetes?
Liu, Shan-Shan
Ding, Ye
Lou, Ji-Quan
CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (04) : 391 - 392
[39] NLRP3, a Potential Therapeutic Target for Type 2 Diabetes?
Shan-Shan Liu
Ye Ding
Ji-Quan Lou
Cardiovascular Drugs and Therapy, 2014, 28 : 391 - 392
[40] The emerging role of TRPV1 in diabetes and obesity
Suri, Anish
Szallasi, Arpad
TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (01) : 29 - 36

← 1 2 3 4 5 →